<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 25 Feb 2021 13:27:47 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>信念医药董事长肖啸：基因治疗的风险、前景和挑战</title><link>https://mp.weixin.qq.com/s/UV8UPnpCaIXOZQF2ucrEfw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcjyNHUYtLjChXEChmOHUUicib6ISLuLb9GSaE4JicUnvWrFyYVZT1Uex7kRbdFH6SJTYc8W6KlNNVA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>基因编辑临床上的应用前景是无限的，中国药企也在紧锣密鼓的布局。]]></content:encoded><pubDate>Thu, 25 Feb 2021 13:06:11 +0800</pubDate></item><item><title>蓝鸟的一波三折，基因治疗的颠簸</title><link>https://mp.weixin.qq.com/s/k50lyXov0m8esPymAA-www</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcjyNHUYtLjChXEChmOHUUPb5pWFpq6jZtOaw533qTOfs6fAJpS8YnGa9slZibeM1ra9CDabc95xQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>击败无情最好的方式是越挫越勇]]></content:encoded><pubDate>Thu, 25 Feb 2021 13:06:11 +0800</pubDate></item><item><title>“睡美人” CAR-T</title><link>https://mp.weixin.qq.com/s/QymMmY9YCRu4fkMS-c-mXA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcjyNHUYtLjChXEChmOHUUHCASZkE1yNKU1ya7hNiaNaXD0rDPtmMSWGgAxOfPQMeb4jwSSTboYyQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Thu, 25 Feb 2021 13:06:11 +0800</pubDate></item><item><title>首款，君实生物PD-1/TGFβ双抗临床申报获受理</title><link>https://mp.weixin.qq.com/s/ke2hAYnS8Slo6xGscrZ_rw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcNREsQ2EkLCo0VnhNLV1NZdV53dC5g4g49SYjUXKHibHRVTaUgn8Y1toZF5wIY8oPlqwP0IpwzOg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:08:43 +0800</pubDate></item><item><title>重磅！CDE发布《基因修饰细胞治疗产品非临床研究与评价技术指导原则》（试行）征求意见</title><link>https://mp.weixin.qq.com/s/kZT0R78r2c7eSscwxXXF2w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcNREsQ2EkLCo0VnhNLV1NfNKIRklUs00L8khVPeQ2Xic1vtibJ2dY7Wgl16ZhBibt3yxEppPbziarjg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷：中国细胞治疗领域生态正式升级]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:08:43 +0800</pubDate></item><item><title>非小细胞肺癌新进展——抗PD-1单抗派安普利+化疗一线治疗鳞状非小细胞肺癌III期临床中期分析达到主要终点</title><link>https://mp.weixin.qq.com/s/dHjQ57fpUaL2-GmqQN33rg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcNREsQ2EkLCo0VnhNLV1NQf5ZoWhzgPvEo28Sia3LNF2tUpyBcJ8icVQLXZqd6ia1b86knZCsMxcjw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>▲佰傲谷2021年TG-Bio第二届免疫技术大会▲今日（2021年2月24日），康方生物科技（开曼）有限公司]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:08:43 +0800</pubDate></item><item><title>君实/微境EGFR-Exon 20插入等非常见突变抑制剂AP-L1898胶囊（JS111）临床申请获NMPA受理</title><link>https://mp.weixin.qq.com/s/FfCvJLOqZ0ReS0hv5XPByQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcNREsQ2EkLCo0VnhNLV1N93PptlmTNXmul8l2JrTN7IxOYo3tEvunWrSTJIlwR21IXSKqTFVmdQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>目前，EGFR-Exon 20插入突变等EGFR非常见突变的非小细胞肺癌患者临床获益十分有限。]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:08:43 +0800</pubDate></item><item><title>冲击一线失败，二线受牵连：阿斯利康撤回PD-L1单抗Imfinzi膀胱癌美国市场</title><link>https://mp.weixin.qq.com/s/GNwgOhgUtijKgffS5mk51A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcNREsQ2EkLCo0VnhNLV1N93PptlmTNXmul8l2JrTN7IxOYo3tEvunWrSTJIlwR21IXSKqTFVmdQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:08:43 +0800</pubDate></item><item><title>开工发才计划</title><link>https://mp.weixin.qq.com/s/jMivtbgtAI3pLSx4gkBbwQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpYcNREsQ2EkLCo0VnhNLV1NHqqiaZBd48QdibK2fuiaD27sYs6hsfibvZ4FdtiaicUpxAOD1zWccPmocdNQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>相亲相完了？打牌打累了？假期结束了吗？那你，对自己满意吗？对未来迷茫吗？对工作有着落吗？如果没有，请收拾行李，来联系我！]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:08:43 +0800</pubDate></item><item><title>风起云涌的ALK-TKI研究，2020年在肺癌领域有哪些新进展</title><link>https://mp.weixin.qq.com/s/Z4oqzoHF-JHMeZ861wMeNg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpa7zlp4ib2RJX6sGwFDBx3zT61zRS4bYGosdDOXeD40VqHzkeaVibrASq36WJlcHUR84ODyrKthPxrA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Tue, 23 Feb 2021 12:10:47 +0800</pubDate></item><item><title>阿达木单抗：百奥泰获批新适应症“儿童斑块状银屑病”，该赛道国内竞争激烈</title><link>https://mp.weixin.qq.com/s/HFsv6wkSJOGf6voVkggQqw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZISIX2ZnaW2s0KrrIdUMcRt33RYlhlf5eFXLAcKaF7KYeLVQhBxbY54sEwFQBT6Ml6N08ib2DhWKQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>适应症的多寡已成为重要因素之一]]></content:encoded><pubDate>Tue, 23 Feb 2021 12:10:47 +0800</pubDate></item><item><title>下一代免疫新星康方生物——Cadonilimab（PD-1/CTLA-4双特异性抗体）获得美国FDA孤儿药资格认定</title><link>https://mp.weixin.qq.com/s/57zmhvPr8dgt36Jbapowkw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZISIX2ZnaW2s0KrrIdUMcRt33RYlhlf5eFXLAcKaF7KYeLVQhBxbY54sEwFQBT6Ml6N08ib2DhWKQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>高速发展的下一代免疫新星]]></content:encoded><pubDate>Tue, 23 Feb 2021 12:10:47 +0800</pubDate></item><item><title>信达生物与驯鹿医疗合作开发的BCMA CAR-T获国家药监局突破性治疗药物认定  用于治疗复发难治性多发性骨髓瘤</title><link>https://mp.weixin.qq.com/s/RgDKaziNyhy0SEBdjGBXaw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpZISIX2ZnaW2s0KrrIdUMcR0na4bw0GLbme6EokqnBLjIcZrqdDcPX4K62AscYHYlvhojQBxwuVOA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷：IBI326是一种针对B细胞成熟抗原的CAR-T细胞疗法。]]></content:encoded><pubDate>Tue, 23 Feb 2021 12:10:47 +0800</pubDate></item><item><title>大咖云集 · 免疫细胞治疗大会4月即将开幕！</title><link>https://mp.weixin.qq.com/s/Ne74mANiO4nds9pwNClMOQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbePLpg9xedXNYwKNOiaVg7sAavHpibBeTBUtybgDvj96ZxrRLQicSFdC7MDlMhBicy2LfNia4HuicsWVGg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>行家荟萃，助力国内细胞基因治疗技术！]]></content:encoded><pubDate>Tue, 23 Feb 2021 12:10:47 +0800</pubDate></item><item><title>专访 | 药明生物李竞博士：早期研究质量决定生物药成败</title><link>https://mp.weixin.qq.com/s/keSJx3vRQB_R8tkyFhN4-w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbWBtxYtD21Zdiaz0sicwf8RMHo8Qic25tw9YdBAcMzTibRHtbNYUiaXzfWGic6bzAwuS64kJY8LXfGm02Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>佰傲谷分享：早期研发质量的合规，决定了产品的成败。]]></content:encoded><pubDate>Mon, 22 Feb 2021 13:03:59 +0800</pubDate></item><item><title>传奇生物2020初步业绩：约2.5亿美元主要用于投资CAR-T产品cilta-cel</title><link>https://mp.weixin.qq.com/s/qCSmeCWv49CJND__WJtp2w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbWBtxYtD21Zdiaz0sicwf8RM12cmribegEe1gtyKmJKnicBTzFBl21iaT6nfY1njBYlrC7Riaz2V7ZnRsQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Mon, 22 Feb 2021 13:03:59 +0800</pubDate></item><item><title>IL-36：炎症与肿瘤</title><link>https://mp.weixin.qq.com/s/brXpBSu9l1UKYbvZ6i3HsA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbWBtxYtD21Zdiaz0sicwf8RMlM2jreQmBUDbTvcFRulwtlR43zYnX6iaXicxoSSh3iawLoRlvws6iaEBkA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Mon, 22 Feb 2021 13:03:59 +0800</pubDate></item><item><title>T for Car-T, G for Gene Therapy</title><link>https://mp.weixin.qq.com/s/1Ewgr7tD7ZEbrsN7GkZtuA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbePLpg9xedXNYwKNOiaVg7sAavHpibBeTBUtybgDvj96ZxrRLQicSFdC7MDlMhBicy2LfNia4HuicsWVGg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>行家荟萃，助力国内细胞基因治疗技术！]]></content:encoded><pubDate>Mon, 22 Feb 2021 13:03:59 +0800</pubDate></item><item><title>靶点药讯48|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/aKjgINDukY9lolE0ADmfDQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpaPvialoSGNoicdhKRic2uvCMZSC3dALXc759EngibBTiaxCrIoRfPl5gmkIXSE8Movav3qGvvLpEdQ06Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>恒瑞医药、百济神州、基石药业、信达生物......]]></content:encoded><pubDate>Sun, 21 Feb 2021 09:18:42 +0800</pubDate></item><item><title>定了！春天不可错过的细胞治疗权威峰会就在上海！</title><link>https://mp.weixin.qq.com/s/r6kOvQJO0DVTrK35keL6rA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/qygMQht6xpbePLpg9xedXNYwKNOiaVg7sAavHpibBeTBUtybgDvj96ZxrRLQicSFdC7MDlMhBicy2LfNia4HuicsWVGg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>行家荟萃，助力国内细胞基因治疗技术！]]></content:encoded><pubDate>Sun, 21 Feb 2021 09:18:42 +0800</pubDate></item></channel></rss>